Response to blinatumomab by genomic subtype
| Subtype . | n (%) . | |||||
|---|---|---|---|---|---|---|
| Patients . | Responders . | Age >50 y . | BM blast >50% . | Prior allogeneic HCT . | Salvage treatment phase ≥third . | |
| Ph-like, CRLF2 rearranged | 16 (38.1) | 12 (75) | 2 (12.5) | 11 (68.8) | 3 (18.8) | 7 (43.8) |
| Ph-like, non-CRLF2 | 7 (16.7) | 4 (57.1) | 1 (14.3) | 2 (28.6) | 2 (28.6) | 2 (28.6) |
| Low hypodiploid | 4 (9.5) | 2 (50) | 1 (25) | 2 (50) | 0 (0) | 2 (50) |
| KMT2A-like* | 3 (7.1) | 3 (100) | 2 (66.7) | 2 (66.7) | 0 (0) | 2 (66.7) |
| B-ALL unclassified | 3 (7.1) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 1 (33.3) | 1 (33.3) |
| Low hyperdiploid | 2 (4.8) | 1 (50) | 0 (0) | 2 (100) | 1 (50) | 2 (100) |
| PAX5alt | 2 (4.8) | 0 (0) | 1 (50) | 0 (0) | 0 (0) | 1 (50) |
| BCR-ABL1 | 2 (4.8) | 0 (0) | 1 (50) | 2 (100) | 2 (100) | 2 (100) |
| DUX4 | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| High hyperdiploid | 1 (2.4) | 0 (0) | 1 (100) | 1 (100) | 0 (0) | 0 (0) |
| TCF3-PBX1 | 1 (2.4) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Subtype . | n (%) . | |||||
|---|---|---|---|---|---|---|
| Patients . | Responders . | Age >50 y . | BM blast >50% . | Prior allogeneic HCT . | Salvage treatment phase ≥third . | |
| Ph-like, CRLF2 rearranged | 16 (38.1) | 12 (75) | 2 (12.5) | 11 (68.8) | 3 (18.8) | 7 (43.8) |
| Ph-like, non-CRLF2 | 7 (16.7) | 4 (57.1) | 1 (14.3) | 2 (28.6) | 2 (28.6) | 2 (28.6) |
| Low hypodiploid | 4 (9.5) | 2 (50) | 1 (25) | 2 (50) | 0 (0) | 2 (50) |
| KMT2A-like* | 3 (7.1) | 3 (100) | 2 (66.7) | 2 (66.7) | 0 (0) | 2 (66.7) |
| B-ALL unclassified | 3 (7.1) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 1 (33.3) | 1 (33.3) |
| Low hyperdiploid | 2 (4.8) | 1 (50) | 0 (0) | 2 (100) | 1 (50) | 2 (100) |
| PAX5alt | 2 (4.8) | 0 (0) | 1 (50) | 0 (0) | 0 (0) | 1 (50) |
| BCR-ABL1 | 2 (4.8) | 0 (0) | 1 (50) | 2 (100) | 2 (100) | 2 (100) |
| DUX4 | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| High hyperdiploid | 1 (2.4) | 0 (0) | 1 (100) | 1 (100) | 0 (0) | 0 (0) |
| TCF3-PBX1 | 1 (2.4) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
Patients with full hematological disease (≥5% blasts; 42 of 44 patients) were included in this table. The 2 patients with only MRD+ disease before receiving blinatumomab (SJALL061895 and SJALL061897) were excluded.
BM, bone marrow.
One KMT2A-like case had USP42-AFF3 fusion; no known driver fusion was identified for the other 2 cases.